Single-use twist for bioreactors, Sartorius Stedim BIOSTAT STR targets faster scale-up

With its BIOSTAT STR single-use bioreactor range, Sartorius Stedim Biotech is pushing automated, disposable systems for upstream bioprocessing from development labs into commercial production. The stainless-steel alternative takes a back seat as single-use bags, sensors and software move center stage.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 8:22 PM ET. Details in the imprint.

Sartorius Stedim Biotech is betting heavily on single-use upstream equipment, and its BIOSTAT STR bioreactor family has become one of the company's flagship platforms for fed-batch and perfusion processes in biologics manufacturing. The stainless-steel alternative remains widely used in legacy plants, but BIOSTAT STR aims to shrink turnaround times and cleaning overhead with fully disposable cultivation bags, integrated sensors and plug-and-play automation for volumes from early clinical to commercial scale. The official Sartorius product page lists working volumes from 12.5 L to 2,000 L and positions the line as a standard for modern single-use facilities.

How the BIOSTAT STR platform is built for single-use upstream work

At the core of BIOSTAT STR are pre-sterilized, gamma-irradiated single-use bioreactor bags that ship ready to install, replacing the traditional stainless vessel, cleaning-in-place and steam-in-place infrastructure that has dominated bioprocessing for decades. These disposable cultivation bags are fitted with integrated pH, dissolved oxygen and temperature sensors, as well as ports for feeds, harvest and sampling, so that operators can connect them to the reactor hardware with minimal aseptic handling steps and no manual assembly of probes or dip tubes.

The hardware frame of each BIOSTAT STR unit houses agitators, load cells, heating and cooling elements and control electronics, while the process contact surfaces are all contained in the bag, which is replaced between batches. According to Sartorius, the range includes nominal volumes around 50 L, 200 L, 500 L, 1,000 L and 2,000 L, allowing drug developers to scale the same single-use process template from development runs into late-stage clinical and commercial production without switching to a different bioreactor geometry.

Automation is anchored by the FlexAct or BioPAT control environment, depending on configuration, which supports standard process strategies such as fed-batch, intensified fed-batch and perfusion with software recipes and data logging aligned with GMP expectations. The controllers integrate upstream analytics like capacitance-based biomass monitoring and off-gas analysis where configured, while also communicating with higher-level plant systems via OPC or comparable interfaces so that BIOSTAT STR lines can be slotted into modern distributed control architectures. In practice, this means biopharma operators can run highly standardized campaigns, copy process parameters from development to production and maintain electronic batch records across multiple scales.

In addition to hardware and software, Sartorius pairs the BIOSTAT STR platform with process development and validation services aimed at biopharma clients that are either moving from stainless steel to single-use or building greenfield single-use plants. Support can include cell culture media optimization, scale-down modeling in small-scale systems, process characterization and technology transfer from originator sites to contract manufacturing partners. The company has highlighted in various presentations that single-use facilities built around systems like BIOSTAT STR often target multi-product flexibility and accelerated changeover between campaigns, which can be critical when handling a mix of monoclonal antibodies, recombinant proteins and newer modalities such as bispecifics.

For biomanufacturers, one of the most tangible attractions of the BIOSTAT STR family is the potential reduction in cleaning, sterilization and validation work that traditionally consumes time and utilities in stainless-steel plants. Because the bag is discarded after each run, cleaning validation burden is shifted largely to supplier qualification and incoming quality controls on the disposable assemblies. This does not remove regulatory expectations around sterility and leachables/extractables, but it changes the balance of in-house versus vendor-managed qualification tasks and can make smaller, modular facilities more economical for medium-volume biologics.

The shift to single-use bioreactors also has implications for facility layout and capital expenditure planning. BIOSTAT STR units do not require the same diameter piping, high-pressure steam boilers or large-scale clean-in-place skids that stainless reactors demand, which can shrink mechanical rooms and simplify remodeling in existing buildings. At the same time, the ongoing cost of bags, filters and other consumables becomes a larger share of the operating budget, creating a trade-off that biopharma companies have to evaluate based on pipeline mix, batch size and campaign frequency. Independent industry analyses of tangential flow and single-use bioreactor markets point to robust demand growth through the next decade as biologics capacity expands and more facilities opt for modular, disposable-based designs. One recent market forecast for tangential flow units underscores how closely upstream and downstream single-use technologies are evolving together.

From a portfolio perspective, BIOSTAT STR sits alongside Sartorius offerings in cell culture media, filtration, chromatography and final fill, forming part of an integrated suite that large and mid-sized biopharma customers can use across the full bioprocess. The company also markets bench and pilot systems that mirror the geometry and control strategies of BIOSTAT STR, giving process development teams the option to work in smaller, less expensive formats while preserving scalability. For contract development and manufacturing organizations, this alignment can be attractive when they are trying to accommodate clients that want to transfer in processes already developed on Sartorius small-scale equipment.

As regulators and health systems push for faster availability of biologics and advanced therapies, demand for flexible manufacturing infrastructure remains high, and systems such as BIOSTAT STR are designed to support that shift from both a technical and operational standpoint. Whether biomanufacturers opt for fully single-use or hybrid facilities that combine stainless steel and disposables, standard platforms that are already widely used in the industry can lower the perceived technology risk relative to custom or one-off designs. Against this backdrop, Sartorius Stedim Biotech continues to emphasize single-use bioprocess solutions as a strategic growth area within its broader equipment and consumables business, reflecting the central role that upstream reactors play in the economics of biologic drug production. The group's investor-relations material regularly highlights demand for single-use systems as a key driver for its bioprocess division.

Within Sartorius Stedim Biotech, the BIOSTAT STR line is positioned as a core enabler for single-use biologics facilities rather than a niche specialty product, anchoring a recurring revenue stream from consumable bags and related components. Shares of Sartorius Stedim Biotech (FR0013154002) are traded on Euronext Paris, where the company is part of the European life sciences equipment sector closely watched by professional investors.

BIOSTAT STR single-use bioreactor in brief

• Product: BIOSTAT STR single-use bioreactor family
• Manufacturer: Sartorius Stedim Biotech SA
• Category: Flagship single-use upstream bioreactor system
• Launch date: First generation introduced in the early 2010s; current generation offered in updated volumes and configurations across the 2020s
• MSRP / Price: Configurations vary widely by volume and options; commercial pricing is typically provided on request in regional currencies
• Availability: Sold directly by Sartorius Stedim Biotech and authorized distributors in major biopharma regions, including North America, Europe and Asia-Pacific
• Target audience: Biopharmaceutical manufacturers, contract development and manufacturing organizations, and advanced therapy producers seeking flexible upstream capacity
• Key differentiator / USP: Scalable single-use platform from development to 2,000 L production scale with integrated automation, disposable bags and process support services

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.